Genotype Variability and Haplotype Profile of Abcb1 (Mdr1) Gene Polymorphisms in Macedonian Population

1. Franke R.M. Gardner E.R and A. Sparreboom, Pharmacogenetics of Drug Transporters Current Pharmaceutical Desig. 2010; 16: 220-230.Search in Google Scholar

2. Zhu Hao-Jie, Wang Jun-Sheng, Markowitz SJ, Donovan LJ, Gibson BB and DeVane CL. Risperidone and Paliperidone Inhibit P-Glycoprotein Activity In Vitro Neuropsychopharmacology. 2007; 32, 757-764.Search in Google Scholar

3. Bruhn O, Cascorbi I. Polymorphisms of drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance. Expert Opin Drug Metab Toxicol. 2014; 10: 1337-54.10.1517/17425255.2014.95263025162314Search in Google Scholar

4. Chandler B, Detsika M, Khoo SH, et al. Factors impacting the expression of membrane-bound proteins in lymphocytes from HIV-positive subjects. J Antimicrob Chemother. 2007; 60: 685-9.10.1093/jac/dkm23017606483Search in Google Scholar

5. Svirnovski AI, Shman TV, Serhiyenka TF, et al. ABCB1 and ABCG2 proteins, their functional activity and gene expression in concert with drug sensitivity of leukemia cells. Hematology (Am Soc Hematol Educ Program). 2009; 14: 204-12.10.1179/102453309X42621819635183Search in Google Scholar

6. Marzolini C, Paus E, Buclin T and Kim R B. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther. 2004; 75 (1): 13-33.10.1016/j.clpt.2003.09.01214749689Search in Google Scholar

7. Gottesman MM, Hrycyna CA, Schoenlein PV, Germann UA and Pastan I. Genetic analysis of the multidrug transporter. Annu Rev Genet 29; 1995; 607-649.10.1146/annurev.ge.29.120195.0031358825488Search in Google Scholar

8. Sugawara I, Kataoka K, Morishita Y, et al. Tissue distribution of P-glycoprotein encoded by a multidrugresistant gene as revealed by a monoclonal antibody. MRK 16. Cancer Res. 48: 1926-1929.Search in Google Scholar

9. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmö ller J, Johne A, et al. Functional polymorphism of the human multidrug-resistance gene: multiple sequence variations and correlations of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA. 2000; 97: 3473-3478.10.1073/pnas.97.7.34731626410716719Search in Google Scholar

10. Nakamura T, Sakaeda T, Horinouchi M, Tamura T, Aoyama N, Schirakawa T, et al. Effect of the mutation (C3435T) et exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther. 2002; 71: 297-303.10.1067/mcp.2002.12205511956513Search in Google Scholar

11. Nikisch G, Eap CB and Baumann P. Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: a pilot study. Pharmacol Res. 2008; 58: 344-347.10.1016/j.phrs.2008.09.01018940259Search in Google Scholar

12. Uhr M, Grauer MT, Yassouridis A and Ebinger M. Blood- brain barrier penetration and pharmacokinetics of amitriptyline and its metabolites in p-glycoprotein (abcb1ab) knock-out mice and controls. J Psychiatr Res. 2007; 41: 179-188.10.1016/j.jpsychires.2005.10.00516387324Search in Google Scholar

13. Gex-Fabry M, Eap CB, Oneda B, Gervasoni N, Aubry JM, Bondolfi G, et al. CYP2D6 and ABCB1 genetic variability: Influence on paroxetine plasma level and therapeutic response. Ther Drug Monit 2008; 30: 474-482.10.1097/FTD.0b013e31817d6f5d18641553Search in Google Scholar

14. Loscher W and Potschka H. Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J Pharmacol Exp Ther. 2002; 301: 7-14.10.1124/jpet.301.1.7Search in Google Scholar

15. Wolf SJ, Bachtiar M, Wang J, Sim TS, Chong SS and Lee CGL, An update on ABCB1 pharmacogenetics: insights from a 3D model into the location and evolutionary conservation of residues corresponding to SNPs associated with drug pharmacokinetics. The Pharmacogenomics Journal. 2011; 11: 315-325.10.1038/tpj.2011.16Search in Google Scholar

16. Tang K, Ngoi SM, Gwee PC, Chua JM, Lee EJ, Chong SS et al. Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics. 2002; 12: 437-450.10.1097/00008571-200208000-00004Search in Google Scholar

17. Kim DH, Lee NY, Sung WJ, Baek JH, Kim JG, Sohn SK, et al. Multidrug resistance as a potential prognostic indicator in acute myeloid leukemia with normal karyotypes. Acta Haematol. 2005; 114(2): 78-83.10.1159/000086579Search in Google Scholar

18. Dulucq S, Bouchet S, Turcq B, Lippert E, Etienne G, Reiffers J, et al. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood. 2008; 112: 2024-2027.10.1182/blood-2008-03-147744Search in Google Scholar

19. Ekhart C, Rodenhuis S, Smits PHM, Beijnen JH, and Huitem, ADR. An overview of the relations between polymorphisms in drug metabolising enzymes and drug transporters and survival after cancer drug treatment. Cancer Treat Rev. 2009; 35: 18-31.10.1016/j.ctrv.2008.07.003Search in Google Scholar

20. Vivona D, Bueno CT, Lima LT, Hirata RDC, Hirata MH, Luchessi AD, et al. ABCB1 haplohaplotype is associated with major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib. Blood Cells Mol Dis. 2012; 48: 132-136.10.1016/j.bcmd.2011.11.001Search in Google Scholar

21. Rubis B, Holysz H, Barczak W, Gryczka R, Lacinski M, et al. Study of ABCB1 polymorphism frequency in breast cancer patients from Poland. Pharmacol Rep. 2012; 64: 1560-1566. 2012.10.1016/S1734-1140(12)70954-4Search in Google Scholar

22. Johne A, Kopke K, Gerloff T, Mai I, Rietbrock S, Meisel C, et al. Modulation of steady-state kinetics of digoxin by haplotypes of the P- glycoprotein MDR1 gene. Clin Pharmacol Ther. 2002; 72(5): 584-94.10.1067/mcp.2002.12919612426522Search in Google Scholar

23. Chowbay B, Cumaraswamy S, Cheung YB, Zhou Q, Lee EJ. Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics. 2003; 13(2): 89-95.10.1097/00008571-200302000-0000512563178Search in Google Scholar

24. Yi SY, Hong KS, Lim HS, Chung JY, Oh DS, Kim JR, et al. A variant 2677A allele of the MDR1 gene affects fexofenadine disposition. Clin Pharmacol Ther. 2004; 76(5): 418-27.10.1016/j.clpt.2004.08.00215536457Search in Google Scholar

25. Tsai CJ, Sauna ZE, Kimchi-Sarfaty C, Ambudkar SV, Gottesman MM, Nussinov R. Synonymous mutations and ribosome stalling can lead to altered folding pathways and distinct minima. J Mol Biol. 2008; 383: 281-291.10.1016/j.jmb.2008.08.012262838918722384Search in Google Scholar

26. Crettol S, Deglon JJ, Besson J, Croquette-Krokar M, Hammig R, Gothuey I, et al. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther. 2006; 80: 668-681.10.1016/j.clpt.2006.09.01217178267Search in Google Scholar

27. Shi YY, He L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res. 2005; 15(2): 97-8.10.1038/sj.cr.729027215740637Search in Google Scholar

28. Li Z, Zhang Z, He Z, Tang W, Li T, Zeng Z, et al. A partition-ligation-combination-subdivision EM algorithm for haplotype inference with multiallelic markers: update of the SHEsis (http://analysis.bio-x-cn). Cell Res. 2009; 19(4): 519-23.10.1038/cr.2009.3319290020Search in Google Scholar

29. Sai K, Kaniwa N, Itoda M, Saito Y, Hasegawa R, Komamura, et al. Haplotype analysis of ABCB1- MDR1 blocks in a Japanese population reveals genotype- dependent renal clearance of irinotecan. Pharmacogenetics. 2003; 13: 741-757.10.1097/00008571-200312000-0000514646693Search in Google Scholar

30. Wasilewska A, Zalewski G, Chyczewski L, and Zoch-Zwierz W. MDR1 gene polymorphisms and clinical course of steroid-responsive nephrotic syndrome in children. Pediatr Nephrol. 2007; 22: 44-51.10.1007/s00467-006-0275-317043887Search in Google Scholar

31. Xu P, Jiang ZP, Zhang BK, Tu JY, and Li HD. Impact of MDR1 haplotypes derived from C1236T, G2677T=A and C3435T on the pharmacokinetics of single-dose oral digoxin in healthy Chinese volunteers. Pharmacology. 2008; 82: 221-227.10.1159/00015648818810246Search in Google Scholar

32. Pechandova D, Buzkova K H, Slanar O, and Perlík F. Polymorphisms of the MDR1 gene in the Czech population. Folia Biol (Praha). 2006; 52: 184-189.Search in Google Scholar

33. Komoto C, Nakamura T, Sakaeda T, Kroetz DL, Yamada T, et al. MDR1 haplotype frequencies in Japanese and Caucasian, and in Japanese patients with colorectal cancer and esophageal cancer. Drug Metab Pharmacokinet. 2006; 21: 126-132.10.2133/dmpk.21.12616702732Search in Google Scholar

34. Lee SS, Kim SY, Kim WY, Thi-Le H, Yoon YR, Yea SS and Shin JG. MDR1 genetic polymorphisms and comparison of MDR1 haplotype profiles in Korean and Vietnamese populations. Ther Drug Monit. 2005; 27: 531-535.10.1097/01.ftd.0000164293.75854.1116044113Search in Google Scholar

35. Halim Salem A, Ali M, Ibrahim A and Ibrahim M. Genotype and Allele Frequencies of MDR-1 Gene Polymorphism in Jordanian and Sudanese Populations American Journal of Medicine Studies. 2014; 1: 19-23.Search in Google Scholar

36. Gonzalez TP, Mucenic T, Brenol JC, Xavier RM, Schiengold M, Chies JA. ABCB1 C1236T, G2677T/A and C3435T polymorphisms in systemic lupus erythematosus patients. Braz J Med Biol Res. 2008; 41(9): 769-72.10.1590/S0100-879X200800090000518820766Search in Google Scholar

37. Sipeky C, Csongei V, Jaromi L, Safrany E, Maasz A, Takacs I, et al. Genetic variability and haplotype profile of MDR1 (ABCB1) in Roma and Hungarian population samples with a review of the literature. Drug Metab Pharmacokinet. 2011; 26(2): 206-15.10.2133/dmpk.DMPK-10-SC-06821178299Search in Google Scholar

38. Marie-Genica Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk. “Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women. Breast Cancer Res Treat. 2010; 120 (3): 727-736.10.1007/s10549-009-0489-819672706Search in Google Scholar

39. Kafka A, Sauer G, Jaeger C, Grundmann R, Kreienberg R, Zeillinger R, Deissler H. Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer. Int J Oncol. 2003; 22(5): 1117-21.10.3892/ijo.22.5.1117Search in Google Scholar

40. Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Meneveau N, et al. Genetic determinants of esponse to clopidogrel and cardiovascular events. N Engl J Med. 2009; 360 (4): 363-375.10.1056/NEJMoa080822719106083Search in Google Scholar

41. Kim DH, Park JY, Sohn SK, Lee NY, Baek JH, Jeon SB, et al. Multidrugresistence-1 gene polymorphisms associated with treatment outcomes in de novo acute myeloid leukemia. Int J Cancer. 2006; 118(9): 2195- 201.10.1002/ijc.2166616331627Search in Google Scholar

42. Siddiqui A, Kerb R, Weale ME, Brinkmann U, Smith A, Goldstein DB, et al. Association of multidrug resistance in epilepsy with a polymorphism in the drugtransporter gene ABCB1. N Engl J Med. 2003; 348(15): 1442-8.10.1056/NEJMoa02198612686700Search in Google Scholar

43. E Shon JH, Yoon YR, Hong WS, Nguyen PM, Lee SS, Choi YG, et al. Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism. Clin Pharmacol Ther. 2005; 78: 191-201.10.1016/j.clpt.2005.04.01216084853Search in Google Scholar

44. F Cavaco I, Gil JP, Gil-Berglund E and Ribeiro V. CYP3A4 and MDR1 alleles in a Portuguese population. Clin Chem Lab Med. 2003; 41: 1345-1350.10.1515/CCLM.2003.20614580164Search in Google Scholar

45. Pan JH, Han JX, Wu JM, Huang HN, Yu QZ and Sheng LJ. MDR1 single nucleotide polymorphism G2677T=A and haplotype are correlated with response to docetaxelcisplatin chemotherapy in patients with non-small-cell lung cancer. Respiration. 2009; 78: 49-55.10.1159/00015845418812689Search in Google Scholar

46. Potocnik U, Glavac D and Dean M. Common germline MDR1/ABCB1 functional polymorphisms and haplotypes modify susceptibility to colorectal cancers with high microsatellite instability. Cancer Genet Cytogenet. 2008; 183: 28-34.10.1016/j.cancergencyto.2008.01.02318474294Search in Google Scholar

47. Wang D, Johnson AD, Papp AC, Kroetz DL and Sadee W. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C T affects mRNA stability. Pharmacogenet. Genomics. 2005; 15: 693-704.Search in Google Scholar

48. Kim RB, Leake BF, Choo EF. et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther. 2001; 70: 189-199.Search in Google Scholar

49. Urayama KY, Wiencke JK, Buffler PA, Chokkalingam AP, Metayer C and Wiemels JL. MDR1 gene variants, indoor insecticide exposure, and the risk of childhood acute lymphoblastic leukemia. Cancer Epidemiol Biomarkers Prev. 2007; 16: 1172-1177.10.1158/1055-9965.EPI-07-000717548681Search in Google Scholar

50. Kurzawski M, Pawlik A, Gornik W and Drozdzik M. Frequency of common MDR1 gene variants in a Polish population. Pharmacol. Rep. 2006; 58: 35-40.Search in Google Scholar

51. Kroetz DL, Pauli-Magnus C, Hodges LM. et al. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics. 2003; 13: 481-494.10.1097/00008571-200308000-0000612893986Search in Google Scholar

52. Gümüş-Akay G, Rüstemoğlu A, Karadağ A, Sunguroğlu A. Haplotype-based analysis of MDR1/ABCB1 gene polymorphisms in a Turkish population. DNA Cell Biol. 2010; 29: 83-90.10.1089/dna.2009.095320025534Search in Google Scholar

53. Bandur S, Petrasek J, Hribova P, Novotna E, Brabcova I and Viklicky O. Haplotypic structure of ABCB1/MDR1 gene modifies the risk of the acute allograft rejection in renal transplant recipients. Transplantation. 2008; 86(9): 1206-13.10.1097/TP.0b013e318187c4d119005401Search in Google Scholar

54. Wong M, Evans S, Rivory LP, Hoskins JM, Mann GJ, Farlow D, et al. Hepatic technetium Tc 99mlabeled sestamibi elimination rate and ABCB1 (MDR1) genotype as indicators of ABCB1 (P-glycoprotein) activity in patients with cancer. Clin Pharmacol Ther. 2005; 77(1): 33-42.10.1016/j.clpt.2004.09.00215637529Search in Google Scholar

55. Panczyk M, Balcerczak E, Piaskowski S, Jamroziak K, Pasz-Walczak G, Mirowski M. ABCB1 gene polymorphisms and haplotype analysis in colorectal cancer. Int J Colorectal Dis. 2009; 24(8): 895-905.10.1007/s00384-009-0724-019415305Search in Google Scholar

56. Sai K, Kaniwa N, Itoda M, Saito Y, Hasegawa R, Komamura K, et al. Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan. Pharmacogenetics. 2003; 13(12): 741-57.10.1097/00008571-200312000-0000514646693Search in Google Scholar

57. Cascorbi I. Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol. Ther. 2006; 112: 457-473.10.1016/j.pharmthera.2006.04.00916766035Search in Google Scholar

58. Tan E.K, Drozdzik M, Bialecka M. et al. Analysis of MDR1 haplotypes in Parkinson's disease in a white population. Neurosci. Lett. 2004; 372: 240-244.Search in Google Scholar

59. Gaikovitch EA, Cascorbi I, Mrozikiewicz PM et al. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur. J. Clin. Pharmacol. 2003; 59: 303-312.Search in Google Scholar

60. Ameyaw MM, Regateiro F, Li T. et al. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 2001; 11: 217-221.10.1097/00008571-200104000-0000511337937Search in Google Scholar

61. Onnie CM, Fisher SA, Pattni R, Sanderson J, Forbes A, Lewis CM, Mathew CG. Associations of allelic variants of the multidrug resistance gene (ABCB1 or MDR1) and inflammatory bowel disease and their effects on disease behavior: a case-control and meta-analysis study. Inflamm Bowel Dis. 2006; 12(4): 263-71.10.1097/01.MIB.0000209791.98866.baSearch in Google Scholar

62. Ho GT, Nimmo ER, Tenesa A, et al. Allelic variations of the multidrug resistance gene determine susceptibility and disease behavior in ulcerative colitis. Gastroenterology. 2005; 128: 288-296.10.1053/j.gastro.2004.11.019Search in Google Scholar

63. Jeannessona E, Albertinia L, Siesta G, Gomesb AM, Ribeirob V, Aslanidisc C, et al. Determination of ABCB1 polymorphisms and haplotypes frequencies in a French population Fundamental and Clinical Pharmacology. 2007; 21: 411-41864. Bernal ML, Sinues B, Fanlo A and Mayayo E. Frequency distribution of C3435T mutation in exon 26 of the MDR1 gene in a Spanish population. Ther. Drug Monit. 2003; 25: 107-111.Search in Google Scholar

65. Vicente J, Sinues B, Fanlo A, Vasquez P, Medina JC, Martinez-Jarreta B. Polymorphism C3435T of the MDR1 gene in Central Americans and Spaniards. Mol Biol Rep. 2008; 35(3): 473-8.10.1007/s11033-007-9109-zSearch in Google Scholar

66. Furuno T, Landi MT, Ceroni M, et al. Expression polymorphism of the blood-brain barrier component Pglycoprotein (MDR1) in relation to Parkinson's disease. Pharmacogenetics. 2002; 12: 529-534.10.1097/00008571-200210000-00004Search in Google Scholar

67. Palmieri O, Latiano A, Valvano R, D'Incà R, Vecchi M, Sturniolo GC, Saibeni S, et al. Multidrug resistance 1 gene polymorphisms are not associated with inflammatory bowel disease and response to therapy in Italian patients. Aliment Pharmacol Ther. 2005; 22(11-12): 1129-38.10.1111/j.1365-2036.2005.02701.xSearch in Google Scholar

68. Petrova DT, Nedeva P, Maslyankov S, Toshev S, Yaramov N, Atanasova S, et al. No association between MDR1 (ABCB1) 2677G > T and 3435C > T polymorphism and sporadic colorectal cancer among Bulgarian patients. Cancer Res Clin Oncol. 2008; 134(3): 317-22.10.1007/s00432-007-0279-9Search in Google Scholar

69. Milojkovic M, Stojnev S, Jovanovic I, Ljubisavljevic S, Stefanovic V, Sunder-Plassman R. Frequency of the C1236T, G2677T/A and C3435T MDR1 gene polymorphisms in the Serbian population. Pharmacol Rep. 2011; 63(3): 808-14.10.1016/S1734-1140(11)70593-XSearch in Google Scholar

70. Sabahi Z, Salek R, Heravi R, Mosaffa F, Avanaki Z and Behravan J. Association of gastric cancer incidence with MDR1 gene polymorphism in an ethnic Iranian population. Indian J Cancer. 2010; 47: 317-321.10.4103/0019-509X.6472320587910Search in Google Scholar

71. Hamdy S I, Hiratsuka M, Narahara K, Endo N, El- Enany M, Moursi N, et al. Genotype and allele frequencies of TPMT, NAT2, GST, SULT1A1 and MDR-1 in the Egyptian population. Br J Clin Pharmacol. 2003; 55: 560-569.10.1046/j.1365-2125.2003.01786.x188426812814450Search in Google Scholar

72. Sapmaz A, Ozen Karatayli SC, Dağli U, Kiliç ZM, Törüner M, Celik Y, et al. Effects of polymorphism in G2677T/A triallelic region of MDR1 gene in Turkish patients with inflammatory bowel disease. Turk J Gastroenterol. 2008; 19(3): 168-73.Search in Google Scholar

73. Omoto CK, Akamura TN, Akaeda TS, Roetz DLK, Amada TY, Matsu HO, et al. Regular article MDR1 haplotype frequencies in Japanese and Caucasian, and in Japanese patients with colorectal cancer and esophageal cancer. Drug Metab Pharmacokinet. 2006; 21: 126-132.10.2133/dmpk.21.12616702732Search in Google Scholar

74. Horinouchi M, Sakaeda T, Nakamura T, Morita Y, Tamura T, Aoyama N, et al. Significant genetic linkage of MDR1 polymorphisms at positions 3435 and 2677: functional relevance to pharmacokinetics of digoxin. Pharm Res. 2002; 19(10): 1581-5.10.1023/A:1020433422259Search in Google Scholar

75. Zheng H, Webber S, Zeevi A, Schuetz E, Zhang J, Lamba J, et al. The MDR1 polymorphisms at exons 21 and 26 predict steroid weaning in pediatric heart transplant patients. Human Immunol. 2002; 63: 765- 770.10.1016/S0198-8859(02)00426-3Search in Google Scholar

76. Li D, Zhang GL, Lou YQ, Li Q, Wang X, Bu XY. Genetic polymorphisms in MDR1 and CYP3A5 haplotype in mainland Chinese Han, Uygur and Kazakh ethnic groups. J Clin Pharm Ther. 2007; 32(1): 89-95.10.1111/j.1365-2710.2007.00791.x17286792Search in Google Scholar

77. Zhang WX, Chen GL, Zhang W, Tan ZR, Liu J, Zhou G, et al. MDR1 genotype do not influence tha absorption of a single oral dose of 100 mg talinolol in healthy Chinese males. Clin Chim Acta. 2005; 359(1- 2): 46-52.10.1016/j.cccn.2005.03.01016170863Search in Google Scholar

78. Kassogue Y, Dehbi H, Nassereddine S, Quachouh M and Nadifi S. Genotype Variability and Haplotype Frequency of MDR1 (ABCB1) Gene Polymorphism in Morocco. DNA and Cell biology. 2013; 32(10): 582-8.10.1089/dna.2013.210823930592Search in Google Scholar

79. http://www.ncbi.nih.gov/pojects/SNP/snp_ref.cgi?rs= 1128503Search in Google Scholar

80. Kimchi-Sarfaty C, Marple AH, Shinar S, Kimchi AM, Scavo D, Roma MI, et al. Ethnicity-related polymorphisms and haplotypes in human ABCB1 gene. Pharmacogenomics. 2007; 8(1): 29-39.10.2217/14622416.8.1.29187674817187507Search in Google Scholar

81. Estrela RC, Ribeiro FS, Carvalho RS, Gregório SP, Dias-Neto E, Struchiner CJ, Suarez-Kurtz G. Distribution of ABCB1 polymorphisms among Brazilians: impact of population admixture. Pharmacogenomics. 2008; 9(3): 267-76.10.2217/14622416.9.3.26718303963Search in Google Scholar